NPY in Brain Fluid Linked to Heart Disease Risk — But the Effect Flips Based on Body Weight

Cerebrospinal fluid NPY levels were associated with cardiovascular risk markers (ApoA-I), but the relationship reversed based on BMI — protective in normal weight individuals but a risk factor in overweight/obese people.

Zhao, Danyang et al.·Nutrition & metabolism·2024·Moderate Evidencecohort
RPEP-09663CohortModerate Evidence2024RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
cohort
Evidence
Moderate Evidence
Sample
N=not reported
Participants
Patients with CSF and blood sampling across BMI categories

What This Study Found

BMI moderates the CSF NPY–peripheral ApoA-I relationship (R²=0.144, β=-0.54, p<0.001). NPY was protective in normal weight (positive ApoA-I association) but a risk factor in overweight/obese (negative ApoA-I association).

Key Numbers

Study examined the NPY-apolipoprotein association across BMI categories, finding significant moderation effects.

How They Did This

Cross-sectional study of 190 participants (73 normal weight, 117 overweight/obese). Measured NPY, ghrelin, orexin A, and oxytocin in CSF via lumbar puncture. Blood ApoA-I and ApoB measured peripherally. Moderation analysis by BMI.

Why This Research Matters

This reveals that brain neuropeptides do not have fixed effects — their impact on cardiovascular risk depends on metabolic state. This could explain why obesity rewires the brain-heart connection and suggests that weight management may be needed to maintain NPY's protective cardiovascular role.

The Bigger Picture

NPY is the most abundant neuropeptide in the brain and a key appetite regulator. This study reveals that the same peptide can be protective or harmful for the heart depending on body composition — a finding with implications for understanding why obesity is such a strong cardiovascular risk factor and how brain peptide signaling changes with weight.

What This Study Doesn't Tell Us

Cross-sectional design cannot establish causation. CSF sampling is invasive, potentially limiting participant selection. The 190-person sample is moderate. ApoA-I and ApoB are surrogate cardiovascular markers, not clinical outcomes.

Questions This Raises

  • ?What mechanism causes NPY's cardiovascular role to reverse in obesity?
  • ?Could weight loss restore NPY's protective association with ApoA-I?
  • ?Do GLP-1 weight-loss drugs affect CSF NPY levels and restore its protective cardiovascular role?

Trust & Context

Key Stat:
Role reversal by BMI Brain NPY is cardiovascular-protective in normal weight but becomes a risk factor in overweight/obese individuals
Evidence Grade:
Moderate evidence: human study with CSF sampling and rigorous moderation analysis, but cross-sectional design and surrogate endpoints limit causal conclusions.
Study Age:
Published in 2024. Novel finding on how metabolic state modulates neuropeptide-cardiovascular connections.
Original Title:
Association of cerebrospinal fluid NPY with peripheral ApoA: a moderation effect of BMI.
Published In:
Nutrition & metabolism, 21(1), 52 (2024)
Database ID:
RPEP-09663

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

How does NPY affect heart disease risk?

NPY's cardiovascular effect depends on body weight. In normal-weight people, higher brain NPY is associated with protective ApoA-I levels. In overweight/obese people, this relationship reverses — higher NPY is associated with lower ApoA-I, a cardiovascular risk factor.

Does losing weight change how NPY affects the heart?

This study did not test weight loss interventions, but the findings suggest that maintaining a healthy weight may be important for preserving NPY's protective cardiovascular role. Future studies should examine whether weight loss reverses the harmful NPY-ApoA-I pattern.

Read More on RethinkPeptides

Cite This Study

RPEP-09663·https://rethinkpeptides.com/research/RPEP-09663

APA

Zhao, Danyang; Han, Xiaoli; Mu, Qingshuang; Wu, Yan; Shan, Ligang; Su, Lidong; Wang, Wenyan; Wang, Pengxiang; Kang, Yimin; Wang, Fan. (2024). Association of cerebrospinal fluid NPY with peripheral ApoA: a moderation effect of BMI.. Nutrition & metabolism, 21(1), 52. https://doi.org/10.1186/s12986-024-00828-6

MLA

Zhao, Danyang, et al. "Association of cerebrospinal fluid NPY with peripheral ApoA: a moderation effect of BMI.." Nutrition & metabolism, 2024. https://doi.org/10.1186/s12986-024-00828-6

RethinkPeptides

RethinkPeptides Research Database. "Association of cerebrospinal fluid NPY with peripheral ApoA:..." RPEP-09663. Retrieved from https://rethinkpeptides.com/research/zhao-2024-association-of-cerebrospinal-fluid

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.